HEALTH CATALYST INC (HCAT) Fundamental Analysis & Valuation

NASDAQ:HCAT • US42225T1079

Current stock price

1.1 USD
0 (0%)
At close:
1.1 USD
0 (0%)
After Hours:

This HCAT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. HCAT Profitability Analysis

1.1 Basic Checks

  • HCAT had positive earnings in the past year.
  • In the past year HCAT had a positive cash flow from operations.
  • In the past 5 years HCAT always reported negative net income.
  • In multiple years HCAT reported negative operating cash flow during the last 5 years.
HCAT Yearly Net Income VS EBIT VS OCF VS FCFHCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M

1.2 Ratios

  • With a Return On Assets value of -35.41%, HCAT is not doing good in the industry: 62.86% of the companies in the same industry are doing better.
  • The Return On Equity of HCAT (-72.41%) is worse than 71.43% of its industry peers.
Industry RankSector Rank
ROA -35.41%
ROE -72.41%
ROIC N/A
ROA(3y)-20.11%
ROA(5y)-19.4%
ROE(3y)-41.21%
ROE(5y)-37.06%
ROIC(3y)N/A
ROIC(5y)N/A
HCAT Yearly ROA, ROE, ROICHCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • With a Gross Margin value of 49.70%, HCAT is not doing good in the industry: 68.57% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of HCAT has remained more or less at the same level.
  • HCAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.66%
HCAT Yearly Profit, Operating, Gross MarginsHCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. HCAT Health Analysis

2.1 Basic Checks

  • HCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, HCAT has more shares outstanding
  • HCAT has more shares outstanding than it did 5 years ago.
  • HCAT has a better debt/assets ratio than last year.
HCAT Yearly Shares OutstandingHCAT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
HCAT Yearly Total Debt VS Total AssetsHCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -3.04, we must say that HCAT is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -3.04, HCAT is doing worse than 68.57% of the companies in the same industry.
  • A Debt/Equity ratio of 0.62 indicates that HCAT is somewhat dependend on debt financing.
  • The Debt to Equity ratio of HCAT (0.62) is worse than 74.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z -3.04
ROIC/WACCN/A
WACC8.7%
HCAT Yearly LT Debt VS Equity VS FCFHCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • A Current Ratio of 1.89 indicates that HCAT should not have too much problems paying its short term obligations.
  • HCAT has a Current ratio (1.89) which is in line with its industry peers.
  • HCAT has a Quick Ratio of 1.89. This is a normal value and indicates that HCAT is financially healthy and should not expect problems in meeting its short term obligations.
  • HCAT has a Quick ratio of 1.89. This is comparable to the rest of the industry: HCAT outperforms 45.71% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.89
HCAT Yearly Current Assets VS Current LiabilitesHCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. HCAT Growth Analysis

3.1 Past

  • HCAT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.14%.
  • HCAT shows a small growth in Revenue. In the last year, the Revenue has grown by 1.48%.
  • The Revenue has been growing by 10.51% on average over the past years. This is quite good.
EPS 1Y (TTM)-32.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)1.48%
Revenue growth 3Y4.05%
Revenue growth 5Y10.51%
Sales Q2Q%-6.19%

3.2 Future

  • HCAT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.70% yearly.
  • Based on estimates for the next years, HCAT will show a small growth in Revenue. The Revenue will grow by 0.58% on average per year.
EPS Next Y91.99%
EPS Next 2Y52.23%
EPS Next 3Y25.7%
EPS Next 5YN/A
Revenue Next Year-8.53%
Revenue Next 2Y-4.17%
Revenue Next 3Y0.58%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HCAT Yearly Revenue VS EstimatesHCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
HCAT Yearly EPS VS EstimatesHCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

7

4. HCAT Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 5.79 indicates a rather cheap valuation of HCAT.
  • Based on the Price/Earnings ratio, HCAT is valued cheaper than 97.14% of the companies in the same industry.
  • HCAT's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.88.
  • A Price/Forward Earnings ratio of 3.02 indicates a rather cheap valuation of HCAT.
  • Based on the Price/Forward Earnings ratio, HCAT is valued cheaper than 100.00% of the companies in the same industry.
  • HCAT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.19.
Industry RankSector Rank
PE 5.79
Fwd PE 3.02
HCAT Price Earnings VS Forward Price EarningsHCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HCAT is valued cheaply inside the industry as 88.57% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 6.5
HCAT Per share dataHCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • HCAT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • HCAT's earnings are expected to grow with 25.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.06
PEG (5Y)N/A
EPS Next 2Y52.23%
EPS Next 3Y25.7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HCAT Dividend Analysis

5.1 Amount

  • No dividends for HCAT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HCAT Fundamentals: All Metrics, Ratios and Statistics

HEALTH CATALYST INC

NASDAQ:HCAT (3/27/2026, 8:23:14 PM)

After market: 1.1 0 (0%)

1.1

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)03-12
Earnings (Next)05-05
Inst Owners76%
Inst Owner Change2.56%
Ins Owners5.31%
Ins Owner Change24.23%
Market Cap80.95M
Revenue(TTM)311.14M
Net Income(TTM)-177.97M
Analysts72.94
Price Target3.95 (259.09%)
Short Float %10.06%
Short Ratio8.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.27%
Min EPS beat(2)-13.81%
Max EPS beat(2)-0.72%
EPS beat(4)2
Avg EPS beat(4)97.84%
Min EPS beat(4)-13.81%
Max EPS beat(4)390.2%
EPS beat(8)4
Avg EPS beat(8)54.81%
EPS beat(12)8
Avg EPS beat(12)417.84%
EPS beat(16)12
Avg EPS beat(16)326.52%
Revenue beat(2)0
Avg Revenue beat(2)-1.23%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)-1.04%
Revenue beat(4)0
Avg Revenue beat(4)-1.48%
Min Revenue beat(4)-1.82%
Max Revenue beat(4)-1.04%
Revenue beat(8)0
Avg Revenue beat(8)-1.59%
Revenue beat(12)2
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-0.8%
PT rev (1m)0%
PT rev (3m)-1.76%
EPS NQ rev (1m)-49.5%
EPS NQ rev (3m)-48.57%
EPS NY rev (1m)-1.38%
EPS NY rev (3m)-0.9%
Revenue NQ rev (1m)-5.26%
Revenue NQ rev (3m)-5.72%
Revenue NY rev (1m)-5.85%
Revenue NY rev (3m)-5.91%
Valuation
Industry RankSector Rank
PE 5.79
Fwd PE 3.02
P/S 0.26
P/FCF N/A
P/OCF 110.74
P/B 0.33
P/tB N/A
EV/EBITDA 6.5
EPS(TTM)0.19
EY17.27%
EPS(NY)0.36
Fwd EY33.16%
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)0.01
OCFY0.9%
SpS4.23
BVpS3.34
TBVpS-0.56
PEG (NY)0.06
PEG (5Y)N/A
Graham Number3.78
Profitability
Industry RankSector Rank
ROA -35.41%
ROE -72.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.7%
FCFM N/A
ROA(3y)-20.11%
ROA(5y)-19.4%
ROE(3y)-41.21%
ROE(5y)-37.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.66%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA 10.53
Cap/Depr 42.68%
Cap/Sales 6.93%
Interest Coverage N/A
Cash Conversion 5.08%
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.89
Altman-Z -3.04
F-Score6
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)38.72%
Cap/Depr(5y)40.28%
Cap/Sales(3y)5.7%
Cap/Sales(5y)6.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y91.99%
EPS Next 2Y52.23%
EPS Next 3Y25.7%
EPS Next 5YN/A
Revenue 1Y (TTM)1.48%
Revenue growth 3Y4.05%
Revenue growth 5Y10.51%
Sales Q2Q%-6.19%
Revenue Next Year-8.53%
Revenue Next 2Y-4.17%
Revenue Next 3Y0.58%
Revenue Next 5YN/A
EBIT growth 1Y34.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.34%
EBIT Next 3Y38.88%
EBIT Next 5YN/A
FCF growth 1Y-1032.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.98%
OCF growth 3YN/A
OCF growth 5YN/A

HEALTH CATALYST INC / HCAT Fundamental Analysis FAQ

What is the fundamental rating for HCAT stock?

ChartMill assigns a fundamental rating of 3 / 10 to HCAT.


Can you provide the valuation status for HEALTH CATALYST INC?

ChartMill assigns a valuation rating of 7 / 10 to HEALTH CATALYST INC (HCAT). This can be considered as Undervalued.


Can you provide the profitability details for HEALTH CATALYST INC?

HEALTH CATALYST INC (HCAT) has a profitability rating of 1 / 10.


What is the valuation of HEALTH CATALYST INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for HEALTH CATALYST INC (HCAT) is 5.79 and the Price/Book (PB) ratio is 0.33.


Can you provide the expected EPS growth for HCAT stock?

The Earnings per Share (EPS) of HEALTH CATALYST INC (HCAT) is expected to grow by 91.99% in the next year.